<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Correction of diabetic <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e> in diabetic patients is the most important factor in reducing cardiac risk </plain></SENT>
<SENT sid="1" pm="."><plain>Diabetic <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e> is characterized by elevated <z:chebi fb="4" ids="17855">triglycerides</z:chebi>, low total <z:chebi fb="6" ids="39025">high-density lipoprotein</z:chebi> (<z:chebi fb="17" ids="39025">HDL</z:chebi>) and small dense <z:chebi fb="2" ids="39026">low-density lipoprotein</z:chebi> (<z:chebi fb="15" ids="39026">LDL</z:chebi>) particles </plain></SENT>
<SENT sid="2" pm="."><plain>The most important therapeutic goal in diabetic <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e> is correction of the non-<z:chebi fb="4" ids="47775">HDL-cholesterol</z:chebi> (<z:chebi fb="0" ids="47775">HDL-C</z:chebi>) level </plain></SENT>
<SENT sid="3" pm="."><plain>Glycaemic control with particular attention to postprandial <z:chebi fb="105" ids="17234">glucose</z:chebi> control plays a role not only in improving <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e> but also in lowering cardiac events </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="8228">Pioglitazone</z:chebi> is particularly effective for improving the manifestations of diabetic <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e>, in addition to its favorable effects on systemic <z:mp ids='MP_0001845'>inflammation</z:mp> and <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Use of <z:chebi fb="0" ids="35664">statins</z:chebi> in addition to lifestyle change is recommended in most if not <z:hpo ids='HP_0000001'>all</z:hpo> type 2 diabetic patients and the goal should be to lower the <z:chebi fb="15" ids="39026">LDL</z:chebi> to a level recommended for the patient with existing <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) (non-<z:chebi fb="0" ids="47775">HDL-C</z:chebi> level &lt;100 mg/dl) </plain></SENT>
<SENT sid="6" pm="."><plain>In addition, therapies for normalization of <z:chebi fb="17" ids="39025">HDL</z:chebi> and <z:chebi fb="0" ids="17855">triglyceride</z:chebi> levels should be deployed </plain></SENT>
<SENT sid="7" pm="."><plain>Most patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (T2D) will require combining a <z:chebi fb="23" ids="18059">lipid</z:chebi>-lowering therapy with therapeutic lifestyle changes to achieve optimal <z:chebi fb="23" ids="18059">lipid</z:chebi> levels </plain></SENT>
<SENT sid="8" pm="."><plain>Combinations usually include two or more of the following: a <z:chebi fb="0" ids="35664">statin</z:chebi>, <z:chebi fb="5" ids="15940">nicotinic acid</z:chebi>, omega-3 fats and <z:chebi fb="0" ids="3098">bile acid</z:chebi> sequestrants (BASs) </plain></SENT>
<SENT sid="9" pm="."><plain>Fibrates may also be of use in diabetic patients with persistently elevated <z:chebi fb="4" ids="17855">triglycerides</z:chebi> and depressed <z:chebi fb="0" ids="47775">HDL-C</z:chebi> levels, although their role in lowering adverse CV events is questionable </plain></SENT>
</text></document>